ProteiQ is a next-generation LC-MS proteomics provider. As a CRO, we partner with pharmaceutical companies and academic groups in biomarker and drug research.
ProteiQ began as a biomarker research company. Realising early the significance of bioinformatics for next-generation proteomics, we developed a world-leading, scalable computational platform for DIA-MS data processing.
By the end of 2018, ProteiQ expanded into a full-service proteomics CRO, opening a wet-lab facility in Potsdam. Since then, we have implemented in-house QC and R&D processes, optimised each step of proteomic analysis.
At ProteiQ, we believe in the transformational power of LC-MS proteomics. Following our motto, “Analyse what matters”, we focus on proteins—because we believe their proximity to expressed phenotype holds the keys to understanding biology, and enabling personalised medicine.
Our purpose is to provide researchers with a cutting-edge gateway to proteomes to achieve next breakthroughs in life sciences —whether in academia, small or large pharmaceutical companies.
We use cutting-edge technology, providing data you can trust.
We decide based on data; that’s our code and our work.
We prize personalization, both for our projects and the world.
We work as a team—within our company, and with our clients.
We emphasise what matters: creating impact through results.